Long-term Safety Study of Odevixibat for Alagille Syndrome
Part of Digestive system, Genetic & congenital, Heart & circulation clinical trials.
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alagille syndrome (a rare genetic liver disease)
- You are starting or already taking odevixibat treatment
- You are at least 6 months old
- You are not enrolled in any other clinical trial testing odevixibat
- You are not enrolled in any other interventional trial for Alagille syndrome
- You have no medical reasons that would make odevixibat unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
This study tracks the safety of odevixibat (a liver medicine) in women who took it during pregnancy or while breastfeeding. It helps patients and doctors understand if the medicine poses any risks.
This study looks at how well Livmarli works for people with Alagille syndrome or a liver disease called PFIC. It uses data from prescriptions to understand the treatment's effects.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
Hear when a new Alagille Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.